
Jan 6 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O:
ARROWHEAD PHARMACEUTICALS ANNOUNCES INTERIM CLINICAL DATA ON RNAI-BASED OBESITY CANDIDATES SHOWING WEIGHT LOSS IN OBESE PATIENTS WITH DIABETES AND IMPROVED MEASURES OF BODY COMPOSITION
ARROWHEAD PHARMACEUTICALS - ARO-INHBE WITH TIRZEPATIDE ACHIEVES -9.4% WEIGHT LOSS
ARROWHEAD PHARMACEUTICALS - ARO-INHBE MONOTHERAPY ACHIEVES -9.9% VISCERAL FAT REDUCTION
ARROWHEAD PHARMACEUTICALS - ARO-ALK7 ACHIEVES -88% REDUCTION IN ALK7 MRNA